Private Advisor Group LLC boosted its stake in shares of Colgate-Palmolive (NYSE:CL - Free Report) by 12.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,231 shares of the company's stock after purchasing an additional 8,279 shares during the quarter. Private Advisor Group LLC's holdings in Colgate-Palmolive were worth $7,021,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Swedbank AB increased its holdings in Colgate-Palmolive by 1.4% in the 3rd quarter. Swedbank AB now owns 2,950,059 shares of the company's stock valued at $306,246,000 after buying an additional 40,324 shares during the period. Sequoia Financial Advisors LLC increased its holdings in Colgate-Palmolive by 0.6% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 20,392 shares of the company's stock valued at $2,117,000 after buying an additional 113 shares during the period. International Assets Investment Management LLC increased its holdings in Colgate-Palmolive by 13,776.8% in the 3rd quarter. International Assets Investment Management LLC now owns 435,871 shares of the company's stock valued at $45,248,000 after buying an additional 432,730 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in Colgate-Palmolive by 4.2% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 20,975 shares of the company's stock valued at $2,177,000 after buying an additional 851 shares during the period. Finally, Assenagon Asset Management S.A. increased its holdings in Colgate-Palmolive by 124.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 437,863 shares of the company's stock valued at $45,455,000 after buying an additional 243,185 shares during the period. 80.41% of the stock is currently owned by institutional investors and hedge funds.
Colgate-Palmolive Price Performance
NYSE CL traded up $1.69 on Friday, hitting $89.56. 4,747,229 shares of the company were exchanged, compared to its average volume of 4,453,167. The company has a current ratio of 0.92, a quick ratio of 0.58 and a debt-to-equity ratio of 13.40. Colgate-Palmolive has a 1-year low of $84.45 and a 1-year high of $109.30. The company has a market cap of $72.68 billion, a P/E ratio of 25.44, a P/E/G ratio of 4.20 and a beta of 0.44. The firm has a 50 day moving average of $88.94 and a two-hundred day moving average of $95.91.
Colgate-Palmolive (NYSE:CL - Get Free Report) last released its earnings results on Friday, January 31st. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.01. Colgate-Palmolive had a net margin of 14.38% and a return on equity of 477.77%. During the same quarter in the prior year, the firm posted $0.87 EPS. On average, equities analysts predict that Colgate-Palmolive will post 3.75 EPS for the current year.
Colgate-Palmolive Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, February 14th. Shareholders of record on Tuesday, January 21st were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 2.23%. Colgate-Palmolive's payout ratio is presently 56.82%.
Analyst Ratings Changes
Several equities research analysts have issued reports on CL shares. Morgan Stanley lowered their price target on shares of Colgate-Palmolive from $111.00 to $104.00 and set an "overweight" rating on the stock in a report on Monday, February 3rd. StockNews.com lowered shares of Colgate-Palmolive from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. Stifel Nicolaus lowered their target price on shares of Colgate-Palmolive from $95.00 to $93.00 and set a "hold" rating on the stock in a report on Monday, February 3rd. TD Cowen lowered their target price on shares of Colgate-Palmolive from $110.00 to $100.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Finally, UBS Group lowered their target price on shares of Colgate-Palmolive from $104.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $101.16.
Get Our Latest Report on Colgate-Palmolive
Colgate-Palmolive Company Profile
(
Free Report)
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.
See Also

Before you consider Colgate-Palmolive, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Colgate-Palmolive wasn't on the list.
While Colgate-Palmolive currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.